Simone Rizzetto @SimoneRizzetto88: "📊 PORTFOLIO UPDATE: Geopolitical Shock,..."

Italy

📊 PORTFOLIO UPDATE: Geopolitical Shock, Biotech Breakthroughs, and Pharma Wins 🚀 One week since the last update and the backdrop shifted dramatically. US-Iran military confrontation dominated the week, with strikes exchanged and the Strait of Hormuz threatened. Oil surged 3% on Monday, VIX jumped 9% to 16.40, and risk-off sentiment rippled through equities. Peace talks are reportedly set to continue. Portfolio holding up through the noise. YTD +14.09%, MTD +1.60%. 📌 Macro: Geopolitical Risk Returns The defining theme was renewed US-Iran escalation. Brent crude reached $78.50 as the Strait of Hormuz faced potential disruption. Markets remain on edge. 📌 Biotech: Catalysts and Upgrades ➤ $GH (Guardant Health Inc): The UnitedHealth coverage win continued to drive momentum. Wall Street upgraded en masse: Citi PT to $215, Evercore ISI to $200, Bernstein to $200, BofA to $190 from $135. Stock hit a 5-year high on July 9 after Freenome results validated Guardant's competitive edge. Some profit-taking followed with a 6.2% pullback. Q2 earnings July 30. ➤ $BBIO (Bridgebio Pharma Inc): Sixth Street and KKR invested $1B in preferred equity at $138 conversion a 100% premium. PROPEL 3 data published in NEJM showed significant body proportionality gains in achondroplasia, NDA filing planned Q3. AstraZeneca's ATTR-CM trial failure cleared the competitive field for Attruby. Stock surged ~17%. 📌 Pharma: FDA Approvals and Pipeline Progress ➤ $MRK (Merck & Co.): FDA approved Keytruda plus Padcev for ALL muscle-invasive bladder cancer patients, first PD-1 plus ADC regimen for MIBC. ~50% recurrence risk reduction. Wells Fargo PT to $150, HSBC to $150 from $135. Stock surged 3.3%. My position up over 52%. House Committee opened probe into Merck's China trials, deadline July 17. ➤ $PFE (Pfizer): FDA approved PADCEV plus Keytruda for all MIBC patients, see above. HSBC downgraded to Hold, appeals court finalized $107.5M patent loss. At 8-9x forward P/E with 7% yield, risk-reward still compelling. 🚀 Tech: Mixed ➤ $META (Meta Platforms Inc): Custom AI chip "Iris" launching September, built by TSMC. Stock surged ~15% in a week, best weekly gain since early 2024. Erste Group upgraded to Buy, consensus Strong Buy at $823. ⏳ Ahead Earning season starting this week. $SPX500 $NSDQ100

Not investment advice. The author may have financial interests in the mentioned instruments.